WO1997039137A1 - Process for the preparation of clavulanic acid - Google Patents
Process for the preparation of clavulanic acid Download PDFInfo
- Publication number
- WO1997039137A1 WO1997039137A1 PCT/GB1997/001007 GB9701007W WO9739137A1 WO 1997039137 A1 WO1997039137 A1 WO 1997039137A1 GB 9701007 W GB9701007 W GB 9701007W WO 9739137 A1 WO9739137 A1 WO 9739137A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- assimilable
- phosphorus
- fermentation
- source
- concentration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title claims abstract description 24
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title claims abstract description 24
- 229960003324 clavulanic acid Drugs 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title abstract description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 50
- 238000000855 fermentation Methods 0.000 claims abstract description 49
- 230000004151 fermentation Effects 0.000 claims abstract description 49
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 26
- 239000011574 phosphorus Substances 0.000 claims abstract description 26
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- 241000187747 Streptomyces Species 0.000 claims abstract description 8
- 241000894007 species Species 0.000 claims abstract description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 235000013312 flour Nutrition 0.000 claims description 11
- 241000187180 Streptomyces sp. Species 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 6
- 230000003698 anagen phase Effects 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical group N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
- 239000001166 ammonium sulphate Substances 0.000 claims description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- 241000187215 Streptomyces jumonjinensis Species 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000187433 Streptomyces clavuligerus Species 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 8
- YTPMCWYIRHLEGM-BQYQJAHWSA-N 1-[(e)-2-propylsulfonylethenyl]sulfonylpropane Chemical compound CCCS(=O)(=O)\C=C\S(=O)(=O)CCC YTPMCWYIRHLEGM-BQYQJAHWSA-N 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 238000004042 decolorization Methods 0.000 description 6
- 239000002028 Biomass Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000424942 Streptomyces clavuligerus ATCC 27064 Species 0.000 description 3
- -1 alkali metal salts Chemical class 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical compound C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- YUWBVKYVJWNVLE-UHFFFAOYSA-N [N].[P] Chemical compound [N].[P] YUWBVKYVJWNVLE-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- IDSXLJLXYMLSJM-UHFFFAOYSA-N morpholine;propane-1-sulfonic acid Chemical compound C1COCCN1.CCCS(O)(=O)=O IDSXLJLXYMLSJM-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Definitions
- This invention relates to a process for preparation of clavulanic acid.
- Clavulanic acid is the common name for (2R, 5R, Z) - 30 ⁇ 2-hydroxyethylidene) -7-oxo-4-oxa-l-azabicyclo[3.2.0]heptane- 2-carboxylic acid.
- Clavulanic acid and its alkali metal salts and esters are active as inhibitors of beta lactamase produced by some Gram positive as well as Gram negative micro-organisms.
- clavulanic acid and alkali metal salts thereof also have a synergistic action with penicillin and cephalosporin antibiotics.
- Clavulanic acid and its salts are used in pharmaceutical preparations to prevent the deactivation of beta lactam antibiotics.
- Commercial preparations contain potassium clavulanate in combination with amoxycillin trihydrate. Potassium clavulanate is more stable than the free acid or other salts.
- Clavulanic acid is prepared by fermentation of micro ⁇ organisms such as strains of Streptomyces for example S.clavuligerus NRRL 3585, S.jumonjinensis NRRL 5741 and S.katsurahamanus IFO 13716 and Streptomyces sp.P6621 FERM P2804.
- the aqueous culture obtained after fermentation is purified and concentrated in accordance with conventional processes for example filtration and chromatographic purification as disclosed in GB 1508977, prior to extraction of the aqueous solution with an organic solvent to obtain a solution of impure clavulanic acid in the solvent.
- WO95/23870 and W096/28452 disclose improved commercial processes for purification of clavulanic acid and preparation of potassium clavulanate.
- Growth of an antibiotic producing micro-organism may include two phases; the growth phase during which biomass is produced and the subsequent stationary phase during which growth does not incur. Secondary metabolites such as antibiotics are usually produced during the stationary phase.
- EP 82522 illustrates use of continuous or intermittent addition of the assimilable carbon source in fermentation of S.clavuligerus NRRL 3585. Regulation of the amount of ammonia is disclosed as W096/18743. Continuous fermentation processes have not been disclosed for clavulanic acid manufacture.
- a process for production of clavulanic acid comprises fermentation of a clavulanic acid producing species of Streptomyces in a fermentation broth containing assimilable sources of carbon and nitrogen, wherein the concentration of phosphorus in the fermentation broth is less than 0.15% w/v.
- the phosphorus concentration is preferably maintained below a limit of 0.15% w/v during the growth phase after which the phosphorus concentration may be allowed to decrease.
- the growth phase for a typical clavulanic acid fermentation lasting for a total of 5 to 6 days may be complete by about 40 hours.
- the source of assimilable phosphorus may be present as a phosphate salt for example sodium or potassium phosphate, sodium or potassium dihydrogen phosphate or disodium or dipotassium hydrogen phosphate or mixtures thereof.
- the phosphorus concentration referred to in this specification is determined as the percentage w/v of phosphorus equivalent to the amount of assimilable phosphorus compound present.
- the phosphorus concentration is preferably 0.0015 to 0.15% w/v, more preferably 0.002 to 0.015% w/v.
- the phosphorus concentration is preferably allowed to reduce to a low value, preferably zero by the 40th hour of fermentation.
- Regulation of the amount of assimilable phosphorus in accordance with the present invention may afford unexpectedly high yields of clavulanic acid.
- the concentration of assimilable carbon source may be selected by routine trials dependent on the characteristics of the Streptomyces strain employed.
- the proportion of a carbon source such as glycerol, glycerol trioleate or corn starch in the starting medium may be higher than 5% w/v and further quantities of a carbon source may be added during the fermentation in accordance with usual fed batch procedures.
- Assimilable nitrogen may be provided by proteinaceous matter in the starting media.
- ammonia may be introduced into the fermenter.
- Ammonia has also been used to regulate the pH of the fermentation broth during the course of the fermentation.
- a high concentration of ammonia can poison the microorganisms and a pH which is too low results in less effective clavulanic acid biosynthesis.
- an assimilable source of nitrogen for example soya bean flour, is added to the starting medium and that an ammonium salt such as ammonium sulphate is added during the course of the fermentation to provide further nitrogen as necessary.
- a nitrogen free compound preferably ammonium hydroxide is used to control pH. This results in a later decrease in the level of biomass than is the case if ammonia is used as the sole nitrogen source and pH regulator.
- the results of a comparison with a classic fermentation are shown in Figure 1.
- the viscosity, which is proportional to the amount of the biomass is shown for a classical fermentation (broken line) and for a fermentation in accordance with the invention (solid line) .
- the assimilable nitrogen source may be flour, for example soya flour or cotton seed flour.
- the amount of assimilable nitrogen is preferably 0.5 to 15% w/v, more preferably l.5 to 7.5% w/v.
- the amount of nitrogen is advantageously greater than 5%.
- the invention relates particularly to fermentation of the Streptomyces species S.clavuligerus NRRL 3585, S.jumonjinensis NRRL 5741 and S.katsurahamanus IFO 13716 and particularly Streptomyces sp.P6621 FERM P2804.
- the invention yield improved yields of clavulanic acid from S.clavuligerus
- the invention finds particular application in relation to commercial scale fermentations particularly but not exceeding broth volumes of IO 4 1, preferably 5 x IO 4 1
- the fermentation broth may be treated as disclosed in our WO95/23870 or by other known methods by which potassium clavulanate of high purity may be prepared.
- the most productive clones of Streptomyces sp. PP 6621 FERM P 2804 were obtained by selection methods. The most productive cultures of this microorganism were stored and were further used as a source for new selection cycles.
- a colony of Streptomyces sp. PP 6621 FERM P 2804 was aseptically transferred in to a sterile potter with sterile water (2cm 3 ) and homogenised. Fragments of the mycelium were transferred onto an agar slope and incubated to maturity (for 10 to 14 days) in a thermostat at 25'C.
- agar surface was overgrown by a grey-green bacterial mycelium. Spores were scraped from the surface, aseptically inoculated into a seed vegetative medium and incubated on a shaker for 24 h at 250 rpm and at 25 * ⁇ 1 * C. Homogeneous suspension of spores from agar slopes may be stored in skimmed milk (which can be used as a protective medium) for more than two months.
- part of the culture was aseptically transferred to a fermentation medium and was incubated on a rotary shaker for 96 h. After the finished fermentation state the content of clavulanic acid was analysed. Cultures which gave the highest yields were used as laboratory inoculum in the fermenter.
- Strains may be stored on slope agar at 4'C maximum for 4 weeks, in skimmed milk in the same condition for 2 months and lyophilised strains may be stored at 4'C for a period of years.
- composition of media for selection of strain for inoculation in the fermenter Composition of media for selection of strain for inoculation in the fermenter
- composition was prepared in accordance with classical methods. Trace elements*
- composition amounts of
- MnSO H 2 0 0.5 g demineralised water to 1000 cm 3
- composition amounts of
- composition amounts of
- Estol (Priolube 1435) 23.0 g glycerol 5.0 g morpholine propane sulphonic acid 12.0 g trace elements* 10.0 ml tap water to 1000 ml Preparation of the laboratory inoculum
- the origin of culture for preparation of laboratory inocula was cultured from an agar slope.
- the chosen slope agar was filled aseptically with sterile water (10cm 3 ) , spores were scraped off and homogenised in a sterile potter.
- the solution of spores was used as a laboratory inoculum.
- composition amounts of
- the inoculum was transferred in a medium that had been sterilised in pre-seed tank and cooled by sterile air to 28 * C.
- the vegetative phase lasted from 50 to 70 hours at a temperature 28" ⁇ 1 * C, pressure 0.3 Bar and with aeration using sterile air and with consistent mixtures.
- the vegetative phase from the pre-seed tank was transferred under pressure into a medium that had been sterilised in the seed fermenter and cooled by sterile air to 28 * C. Air was sterilised by filters with a pore size of 0.2 ⁇ m.
- the vegetative phase lasted from 10 to 20 h at 28' ⁇ l'C, pressure 0.3 Bar, aeration by sterile air and constant mixing.
- Synperonic (registered trade mark of ICI GB) is a propylenglycol antifoam agent * Soybean oil can be used instead of Estol.
- the broth was mixed and aerated during the course of whole fermentation and the pH of the media was maintained by addition of 25% aqueous solution of ammonium hydroxide at value 6.8 - 6.9.
- the fermentation lasted for 96h and the resultant concentration of clavulanic acid was 3580 mg/1.
- the concentration of phosphorus after the 51st hour of the fermentation was below the detection limit.
- Example IB A medium used with the same proportions of ingredients as Example IB was placed in two stainless steel fermenters (5001 each) .
- the fermentation in the first fermenter was run under the same conditions as were described in the Example IB.
- the fermentation conditions in second fermenter differed from that described in Example IB only in that an 11% aqueous solution of ammonium sulphate at 9 cm 3 /l was added to the fermentation broth during the period between the 40th and 60th hours following inoculation.
- the pH was maintained on the desired level by sodium hydroxide. After the 60th hour we stopped the addition of nitrogen source was stopped.
- the viscosity of the fermentation broth which is proportional to the amount of biomass, was analysed during the course of fermentation.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97916544A EP0906446A1 (en) | 1996-04-12 | 1997-04-11 | Process for the preparation of clavulanic acid |
JP53684297A JP2001503244A (en) | 1996-04-12 | 1997-04-11 | Preparation of clavulanic acid |
PL97329291A PL185620B1 (en) | 1996-04-12 | 1997-04-11 | Method of obtaining clavulanic acid |
AU25164/97A AU2516497A (en) | 1996-04-12 | 1997-04-11 | Process for the preparation of clavulanic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SIP-9600120 | 1995-04-12 | ||
SI9600120A SI9600120A (en) | 1996-04-12 | 1996-04-12 | New and improved fermentative procedure for the production of clavulanic acid and its salts |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997039137A1 true WO1997039137A1 (en) | 1997-10-23 |
Family
ID=20431824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/001007 WO1997039137A1 (en) | 1996-04-12 | 1997-04-11 | Process for the preparation of clavulanic acid |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0906446A1 (en) |
JP (1) | JP2001503244A (en) |
AU (1) | AU2516497A (en) |
CA (1) | CA2251596A1 (en) |
PL (1) | PL185620B1 (en) |
RU (1) | RU2188868C2 (en) |
SI (1) | SI9600120A (en) |
WO (1) | WO1997039137A1 (en) |
ZA (1) | ZA973139B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998054352A1 (en) * | 1997-05-28 | 1998-12-03 | Dsm N.V. | Fermentative production of clavulanic acid under controlled phosphate conditions |
WO2000018947A1 (en) * | 1998-09-29 | 2000-04-06 | Dsm N.V. | Fermentation of clavulanic acid at a controlled level of ammonia |
EP0811689B1 (en) * | 1995-11-23 | 2002-06-12 | Antibioticos, S.A. | Process for the production of clavulanic acid and/or salts thereof |
US6440708B1 (en) * | 1998-09-29 | 2002-08-27 | Dsm N.V. | Fermentation of clavulanic acid at a controlled level of ammonia |
EP2589663A1 (en) | 2011-11-04 | 2013-05-08 | LEK Pharmaceuticals d.d. | Process for production of clavulanic acid |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2328045A1 (en) * | 1975-10-13 | 1977-05-13 | Beecham Group Ltd | CLAVULANIC ACID PRODUCTION PROCESS |
US4110165A (en) * | 1974-04-20 | 1978-08-29 | Beecham Group Limited | Process for the production of clavulanic acid |
US4144242A (en) * | 1975-02-07 | 1979-03-13 | Glaxo Laboratories Limited | Process for the purification of clavulanic acid |
GB1571888A (en) * | 1977-02-04 | 1980-07-23 | Glaxo Lab Ltd | Clavulanic acid production |
EP0182522A1 (en) * | 1984-10-27 | 1986-05-28 | Beecham Group p.l.c. | Preparation of clavulanic acid and its salts and esters |
-
1996
- 1996-04-12 SI SI9600120A patent/SI9600120A/en not_active IP Right Cessation
-
1997
- 1997-04-11 CA CA002251596A patent/CA2251596A1/en not_active Abandoned
- 1997-04-11 WO PCT/GB1997/001007 patent/WO1997039137A1/en not_active Application Discontinuation
- 1997-04-11 RU RU98120408/13A patent/RU2188868C2/en not_active IP Right Cessation
- 1997-04-11 EP EP97916544A patent/EP0906446A1/en not_active Withdrawn
- 1997-04-11 JP JP53684297A patent/JP2001503244A/en active Pending
- 1997-04-11 PL PL97329291A patent/PL185620B1/en not_active IP Right Cessation
- 1997-04-11 AU AU25164/97A patent/AU2516497A/en not_active Abandoned
- 1997-04-14 ZA ZA973139A patent/ZA973139B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110165A (en) * | 1974-04-20 | 1978-08-29 | Beecham Group Limited | Process for the production of clavulanic acid |
US4144242A (en) * | 1975-02-07 | 1979-03-13 | Glaxo Laboratories Limited | Process for the purification of clavulanic acid |
FR2328045A1 (en) * | 1975-10-13 | 1977-05-13 | Beecham Group Ltd | CLAVULANIC ACID PRODUCTION PROCESS |
GB1571888A (en) * | 1977-02-04 | 1980-07-23 | Glaxo Lab Ltd | Clavulanic acid production |
EP0182522A1 (en) * | 1984-10-27 | 1986-05-28 | Beecham Group p.l.c. | Preparation of clavulanic acid and its salts and esters |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 95, no. 3, 20 July 1981, Columbus, Ohio, US; abstract no. 22886g, LILLEY, G ET AL.: "Control of the production of cephamycin C and thienamycin by Streptomyces cattleya NRRL 8057" page 516; XP002035709 * |
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; DEMAIN A L: "PRODUCTION OF BETA LACTAM ANTIBIOTICS AND ITS REGULATION.", XP002035710 * |
J.CHEM.TECHNOL.BIOTECHNOL., vol. 31, no. 2, 1981, pages 127 - 134 * |
PROC NATL SCI COUNC REPUB CHINA PART B LIFE SCI 15 (4). 1991. 251-265. CODEN: PNBSEF ISSN: 0255-6596 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0811689B1 (en) * | 1995-11-23 | 2002-06-12 | Antibioticos, S.A. | Process for the production of clavulanic acid and/or salts thereof |
WO1998054352A1 (en) * | 1997-05-28 | 1998-12-03 | Dsm N.V. | Fermentative production of clavulanic acid under controlled phosphate conditions |
WO2000018947A1 (en) * | 1998-09-29 | 2000-04-06 | Dsm N.V. | Fermentation of clavulanic acid at a controlled level of ammonia |
US6440708B1 (en) * | 1998-09-29 | 2002-08-27 | Dsm N.V. | Fermentation of clavulanic acid at a controlled level of ammonia |
US6991925B2 (en) | 1998-09-29 | 2006-01-31 | Dsm Ip Assets B.V. | Fermentation of clavulanic acid at a controlled level of ammonia |
EP2589663A1 (en) | 2011-11-04 | 2013-05-08 | LEK Pharmaceuticals d.d. | Process for production of clavulanic acid |
WO2013064687A2 (en) | 2011-11-04 | 2013-05-10 | Lek Pharmaceuticals D.D. | Process for production of clavulanic acid |
Also Published As
Publication number | Publication date |
---|---|
RU2188868C2 (en) | 2002-09-10 |
EP0906446A1 (en) | 1999-04-07 |
ZA973139B (en) | 1998-08-05 |
AU2516497A (en) | 1997-11-07 |
JP2001503244A (en) | 2001-03-13 |
CA2251596A1 (en) | 1997-10-23 |
PL185620B1 (en) | 2003-06-30 |
SI9600120A (en) | 1997-12-31 |
PL329291A1 (en) | 1999-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1239362A (en) | Method for the production of 6-hydroxynicotinic acid | |
DK165124B (en) | METHOD OF PREPARING A 5-HYDROXY-S541 MACROLIDE COMPOUND | |
JP3313730B2 (en) | Method for producing clavulanic acid and / or its salt | |
WO1997039137A1 (en) | Process for the preparation of clavulanic acid | |
CA2129416A1 (en) | Fermentation process for preparation of antihypercholesteremic products | |
EP1613759B1 (en) | Fermentation processes with low concentrations of carbon- and nitrogen-containing nutrients | |
KR100317901B1 (en) | A microorganism producing glutamic acid and a method for producing glutamic acid using said microorganism | |
US6197560B1 (en) | Metabolic controlled fermentation procedure for the manufacture of lovastatin hydroxy acid | |
CA2289553C (en) | Metabolic controlled fermentation procedure for the manufacture of lovastatin hydroxy acid | |
KR100317902B1 (en) | A microorganism producing glutamic acid and a method for producing glutamic acid using said microorganism | |
WO2007029082A2 (en) | An improved fermentation process for preparing ascomycin | |
KR100446110B1 (en) | Cephalosporin c-producing microorganism having tolerance against high concentration of glycerol | |
GB1571888A (en) | Clavulanic acid production | |
US6440708B1 (en) | Fermentation of clavulanic acid at a controlled level of ammonia | |
SI9600121A (en) | Process for the preparation of clavulanic acid and its salts | |
CA1076120A (en) | Clavulanic acid esters | |
WO1998054352A1 (en) | Fermentative production of clavulanic acid under controlled phosphate conditions | |
JPH0597858A (en) | Alanolosinol-a and alanolosinol-b, prepara- tion thereof, and use thereof | |
JPH04234995A (en) | Production of d-pantolactone | |
CZ241295A3 (en) | High-production strain of penicillium chrysogenum ccm 8197 micro-organism | |
GB2114978A (en) | Microbiological process for preparing nebramycin-2, nebramycin-5' and nebramycin-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997916544 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2251596 Country of ref document: CA Ref country code: CA Ref document number: 2251596 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 536842 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997916544 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997916544 Country of ref document: EP |